{"nctId":"NCT00686920","briefTitle":"Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy","startDateStruct":{"date":"2007-03-07","type":"ACTUAL"},"conditions":["Hepatic Encephalopathy"],"count":322,"armGroups":[{"label":"Rifaximin","type":"EXPERIMENTAL","interventionNames":["Drug: Rifaximin"]}],"interventions":[{"name":"Rifaximin","otherNames":["Xifaxan®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must sign an Informed Consent Form\n* In remission from past HE\n* Appropriate birth control measures\n* More than or equal to 18 years of age\n* Must be potential for benefit from treatment\n* Recent HE episodes\n* Capable and willing to comply with all study procedures\n* Participant has support network\n\nExclusion Criteria:\n\n* Significant medical conditions or Investigator decision not to include the participant\n* Allergies to the study drug or similar drugs\n* Laboratory abnormalities\n* Recent participation in another clinical trial\n* Problems experienced in a previous HE trial\n* Pregnant or at risk of pregnancy\n* Recent alcohol consumption\n* Active or latent bacterial or viral Infections\n* Bowel issues\n* Recent Active Cancer\n* On a prohibited medication","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Number Of Participants With Postbaseline Potentially Clinically Significant Laboratory (Hematology and Blood Chemistry) Abnormal Results In ≥5% of Participants","description":"Hematology and blood chemistry with potentially significant values included: Hemoglobin \\<9, \\>18, or ≥3 (grams/deciliter \\[g/dL\\]) decrease from previous visit or ≥4 g/dL decrease from baseline; Hematocrit \\<0.27%, \\>0.54%, or ≥0.10% decrease from previous visit or ≥0.15% decrease from baseline; Platelets \\<50 or \\>400\\*10\\^9/(liter \\[L\\]); Prothrombin time 9 seconds above baseline or upper limit of normal range; International normalized ratio \\>1.7; White blood cells \\<2.0 or \\>12.0\\*10\\^9/L; Lymphocytes \\<13.5% or \\>70%; Glucose, random, serum \\<2.2 or \\>16.5 millimole (mmol)/L; Potassium ≤3.0 or ≥5.5 mmol/L; Direct bilirubin increases 3-fold from baseline or \\>85.5 micromole (umol)/L. Baseline value was defined as the last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Number Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event","description":"A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Number Of Participants With A Significant Mean Change From Baseline In Vital Signs","description":"Vital signs were measured and included sitting blood pressure, heart rate, oral temperature, and weight. These were collected at each scheduled study visit. Participants were placed supine for 5 minutes prior to each assessment of vital signs. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline In Conn Score At Last Assessment","description":"The assessment for change in mental status during the study was measured by the Conn score (also known as the West Haven score). The following scale was used in the Conn scoring system: Grade 0=No personality or behavioral abnormality detected. Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span; or impairment of addition or subtraction. Grade 2=Lethargy; disorientation for time; obvious personality change; and inappropriate behavior. Grade 3=Somnolence to semi-stupor, responsive to stimuli; confused; gross disorientation; and bizarre behavior. Grade 4=Coma, unable to test mental state. Participants entered the study with a Conn score of 0 to 2. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.58"},{"groupId":"OG001","value":"0.2","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.77"},{"groupId":"OG001","value":"0.1","spread":"0.41"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":158,"n":252},"commonTop":["Nausea","Urinary tract infection","Oedema peripheral","Hypokalaemia","Ascites"]}}}